TRVI

Investor Conferences Participation: Trevi Therapeutics, Inc. will participate in several investor conferences in April 2025, including the Needham Virtual Healthcare Conference and the Piper Sandler Spring Biopharma Symposium, with presentations led by CEO Jennifer Good.

Haduvio™ Development: The company is developing Haduvio™ (oral nalbuphine ER) as a potential treatment for chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), conditions that currently lack approved therapies.

Leadership Change at Avalo Therapeutics: Michael Heffernan has been appointed as the new Chairman of the Board of Directors for Avalo Therapeutics, succeeding Dr. Garry Neil, who remains as CEO and board member.

Focus on Immune Dysregulation Treatments: Avalo is advancing its pipeline of therapies for immune-mediated diseases, particularly highlighting its lead candidate AVTX-009, which is currently in Phase 2 trials for hidradenitis suppurativa.

Stock Performance and Financial Results: Trevi Therapeutics (TRVI) stock surged over 63% following positive clinical trial results for its treatment Haduvio, which targets chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough. The company also reported Q4 earnings that exceeded expectations, prompting analysts to raise price targets significantly.

Clinical Trial Success: Trevi's Phase 2a RIVER trial demonstrated a significant reduction in cough frequency for patients with refractory chronic cough, indicating the potential effectiveness of Haduvio. Analysts have rated the stock as a Strong Buy, with an average price target suggesting a potential upside of over 166%.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Clinical Trial Updates: Trevi Therapeutics announced positive topline data from the Phase 2a RIVER trial for Haduvio, showing significant reduction in cough frequency in patients with refractory chronic cough. The Phase 2b CORAL trial has completed enrollment, with results expected in Q2 2025.

Financial Overview: The company ended 2024 with $107.6 million in cash and equivalents, indicating a financial runway into the second half of 2026, despite reporting a net loss of $47.9 million for the year.

Conference Call Announcement: Trevi Therapeutics, Inc. will host a conference call and live audio webcast on March 18, 2025, at 4:30 p.m. ET to provide a corporate update and review financial results for the year ended December 31, 2024.

About Haduvio™: The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), conditions that currently lack approved therapies and significantly impact patient quality of life.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

U.S. Stock Market Overview: U.S. stocks declined, with the Nasdaq Composite dropping about 650 points; however, Redfin Corporation shares surged 70% after Rocket Companies announced an acquisition deal valued at $12.50 per share.

Notable Stock Performances: Several companies saw significant gains, including Mineralys Therapeutics (up 53%), Trevi Therapeutics (up 41.8%), and Protagonist Therapeutics (up 41%), following positive trial results for their respective products.

BioNTech SE Analysis: J.P. Morgan analyst Jessica Fye maintains a Hold rating on BioNTech SE with a price target of $120, while the consensus among analysts is a Strong Buy with an average target of $143.03.

Trevi Therapeutics Update: H.C. Wainwright analyst Oren Livnat reiterates a Buy rating for Trevi Therapeutics with a price target of $12.50, and the overall analyst consensus suggests a Strong Buy with a target of $15.19, indicating significant upside potential.

Trial Results: Trevi Therapeutics reported positive topline results from its Phase 2a RIVER trial for Haduvio, showing a significant reduction in chronic cough frequency by 67% from baseline and 57% on a placebo-adjusted basis, with 84% of patients experiencing at least a 30% reduction.

Safety and Stock Impact: The safety profile was consistent with previous trials, with common side effects including constipation and nausea; following the announcement, Trevi's stock surged by over 40%.

Analyst Upgrade: H.C. Wainwright analyst Oren Livnat raised Trevi Therapeutics' price target to $12.50 from $7.50, maintaining a Buy rating following positive results from the RIVER Phase 2a study of Haduvio for refractory chronic cough, which were described as a "homerun."

Investor Confidence: The significant reduction in cough symptoms observed in the study is expected to boost investor confidence regarding the success of Trevi's clinical programs and potential FDA approval.

NASDAQ 100 Pre-Market Performance: The NASDAQ 100 is down by 350.25 points, with a total pre-market volume of over 106 million shares traded.

Most Active Stocks: Redfin Corporation shows significant gains, while other stocks like Direxion Daily TSLA Bull 2X Shares and NVIDIA Corporation are experiencing declines in their pre-market trading.

Analyst Ratings on Healthcare Stocks: Analysts have expressed bullish sentiments towards Trevi Therapeutics, Oncolytics Biotech, and Takeda Pharmaceutical Company, with Trevi receiving a Strong Buy consensus and price targets indicating significant upside potential.

Individual Stock Insights: Trevi Therapeutics has a price target of $11.81, Oncolytics Biotech is rated with a Moderate Buy and a target of $4.00, while Takeda also holds a Moderate Buy rating close to its 52-week high.

Checkpoint Therapeutics Acquisition: Checkpoint Therapeutics shares surged 66% to $4.10 in pre-market trading following Sun Pharma's announcement of a $355 million acquisition deal.

Pre-Market Stock Movements: Several stocks experienced significant changes in pre-market trading, with notable gainers including AtlasClear Holdings (up 79.9%) and Trevi Therapeutics (up 25.4%), while losers included Able View Global (down 26.4%) and SUNation Energy (down 18.2%).

Haduvio Trial Results: Trevi Therapeutics announced that Haduvio, an investigational therapy for chronic cough, achieved a statistically significant 57% reduction in 24-hour cough frequency compared to placebo in its Phase 2a RIVER trial, demonstrating efficacy across various cough severities.

Next Steps and Impact: The company plans to discuss further development with the FDA, aiming to address the unmet needs of patients suffering from refractory chronic cough, which significantly impacts their quality of life.

Upgrade of Trevi Therapeutics: Raymond James has upgraded Trevi Therapeutics (TRVI) to Strong Buy from Outperform, raising the price target to $29 after Haduvio showed significant efficacy in reducing cough in a Phase 2a trial.

Clinical Trial Success: The trial reported a 57% placebo-adjusted reduction in cough at Day 21, outperforming expectations and previous results, indicating strong potential for Haduvio compared to competitors.

Trevi Therapeutics (TRVI): Analysts maintain a Buy rating on Trevi Therapeutics with a price target of $25.00, indicating a potential upside of 175.3% from its current share price of $4.30.

Cross Country Healthcare (CCRN): Cross Country Healthcare receives a Hold rating with a price target of $18.61, suggesting an 18.1% upside from its current share price of $15.93.

Conference Call Announcement: Trevi Therapeutics will host a conference call and webcast on March 10, 2025, at 8:30 a.m. ET to share topline results from the Phase 2a RIVER trial of their investigational therapy Haduvio for refractory chronic cough.

About Refractory Chronic Cough: This condition affects approximately 2-3 million patients in the U.S. and currently has no approved therapies, causing significant social and economic burdens due to its debilitating nature.

Conference Call Announcement: Trevi Therapeutics will hold a conference call and live webcast on March 10, 2025, at 8:30 a.m. ET to present topline results from the Phase 2a RIVER trial of their investigational therapy Haduvio for refractory chronic cough.

About Refractory Chronic Cough: Refractory chronic cough affects approximately 2-3 million patients in the U.S., has no approved therapies, and significantly impacts quality of life, with potential complications including social embarrassment and sleep disruption.